Abeona Therapeutics (NASDAQ:ABEO) Earns Buy Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Abeona Therapeutics (NASDAQ:ABEO - Free Report) in a research report sent to investors on Monday, MarketBeat reports. The firm currently has a $15.00 price target on the biopharmaceutical company's stock. HC Wainwright also issued estimates for Abeona Therapeutics' Q1 2025 earnings at ($0.36) EPS, Q3 2025 earnings at ($0.29) EPS, Q4 2025 earnings at ($0.13) EPS, FY2025 earnings at ($1.11) EPS, Q1 2026 earnings at ($0.10) EPS, Q2 2026 earnings at ($0.06) EPS, Q3 2026 earnings at ($0.01) EPS, Q4 2026 earnings at $0.05 EPS and FY2026 earnings at ($0.12) EPS.

A number of other brokerages have also issued reports on ABEO. Oppenheimer began coverage on Abeona Therapeutics in a research note on Wednesday, March 5th. They issued an "outperform" rating and a $16.00 price target on the stock. StockNews.com downgraded shares of Abeona Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, February 22nd. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $17.50.

Remove Ads

Abeona Therapeutics Trading Down 1.3 %

Shares of NASDAQ:ABEO traded down $0.07 during trading on Monday, reaching $4.98. The stock had a trading volume of 312,970 shares, compared to its average volume of 336,576. Abeona Therapeutics has a fifty-two week low of $3.05 and a fifty-two week high of $8.45. The business has a fifty day moving average price of $5.42 and a 200-day moving average price of $5.81. The stock has a market cap of $216.27 million, a P/E ratio of -1.84 and a beta of 1.79. The company has a quick ratio of 6.12, a current ratio of 6.12 and a debt-to-equity ratio of 0.31.

Abeona Therapeutics (NASDAQ:ABEO - Get Free Report) last issued its quarterly earnings results on Thursday, March 20th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, topping analysts' consensus estimates of ($0.43) by $0.19. As a group, analysts anticipate that Abeona Therapeutics will post -1.16 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Abeona Therapeutics

Several institutional investors have recently bought and sold shares of the business. Wellington Management Group LLP acquired a new position in shares of Abeona Therapeutics during the 4th quarter valued at $520,000. Western Standard LLC lifted its stake in shares of Abeona Therapeutics by 22.8% during the fourth quarter. Western Standard LLC now owns 2,084,418 shares of the biopharmaceutical company's stock worth $11,610,000 after purchasing an additional 386,321 shares in the last quarter. Squarepoint Ops LLC purchased a new stake in shares of Abeona Therapeutics in the fourth quarter worth about $67,000. Twinbeech Capital LP acquired a new stake in shares of Abeona Therapeutics in the fourth quarter valued at about $58,000. Finally, OMERS ADMINISTRATION Corp purchased a new stake in shares of Abeona Therapeutics during the 4th quarter valued at about $362,000. 80.56% of the stock is currently owned by hedge funds and other institutional investors.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.